In research models, LL-37 has been observed to disrupt microbial membranes through electrostatic interactions, while also modulating immune cell recruitment, cytokine production, and wound-model signalling. Studies note it neutralizes bacterial endotoxins (LPS) and can penetrate and disrupt established biofilms. Areas of research interest include: Broad-spectrum antimicrobial activity studied in research; Bacterial biofilm disruption investigated in models; Immune response modulation reported in studies.
Is LL-37 third-party tested?
Yes. Each batch of LL-37 is analyzed by an independent third-party laboratory. Batch LL301 (results dated November 28, 2025) reported average purity of 98.64% and average mass of 10.07 mg. Full Certificate of Analysis documentation is available for this product.
What does published research say about LL-37?
Extensively studied as a key innate immune defence molecule. Published research demonstrates broad antimicrobial efficacy, biofilm disruption capabilities, and immune-modulatory properties. Research applications continue to expand. This page cites 1 published reference for further reading.
Who typically studies LL-37 in a laboratory setting?
This peptide is supplied as a lyophilized (freeze-dried) powder. Bacteriostatic water is required to reconstitute it before use and is not included with this product. Store lyophilized (powder) form at room temperature or refrigerated. After reconstitution, store refrigerated (2-8°C) and use within 30 days.
Where can I buy LL-37 in Canada?
MyPeptide is a Canadian supplier of research peptides based in Mississauga, Ontario. LL-37 is stocked domestically and ships to research customers nationwide — including Toronto, Vancouver, Calgary, Edmonton, Ottawa, and Montreal. Every order includes third-party Certificate of Analysis documentation for the batch shipped.
Does MyPeptide ship LL-37 across Canada?
Yes. LL-37 ships from within Canada to every province and territory, with fast domestic delivery and no international customs delays. Orders are dispatched with tracking, and all products are sold strictly for laboratory and research use only.
Research peptide reference page
LL-37
The only human cathelicidin antimicrobial peptide, studied in research as a key component of the innate immune system with broad-spectrum antimicrobial activity against bacteria, viruses, fungi, and biofilms.
CAS number: 154947-66-7.
In research models, LL-37 has been observed to disrupt microbial membranes through electrostatic interactions, while also modulating immune cell recruitment, cytokine production, and wound-model signalling. Studies note it neutralizes bacterial endotoxins (LPS) and can penetrate and disrupt established biofilms.
LL-37 is supplied for laboratory research use only. It is not for human or animal use, clinical use, diagnostic use, therapeutic use, or personal-use protocols.
Each MyPeptide reference page is organized around product identity, documentation, and research context rather than medical claims, dosing instructions, or personal-use outcomes.
Use the related links on this page to move between the catalog, COA records, policy pages, and supporting research guides while staying within the research-use-only scope.
Batch documentation, product identity, and compliance context are kept close together so qualified purchasers can review the material before continuing through the storefront.
Research context
Extensively studied as a key innate immune defence molecule. Published research demonstrates broad antimicrobial efficacy, biofilm disruption capabilities, and immune-modulatory properties. Research applications continue to expand.
Store lyophilized (powder) form at room temperature or refrigerated. After reconstitution, store refrigerated (2-8°C) and use within 30 days.
